GSK plc (LON:GSK) Insider Purchases £126.72 in Stock

Key Points

• GSK plc insider Julie Brown purchased 9 shares at an average price of GBX 1,408 ($18.91), totaling £126.72 ($170.21) on August 11th.
• The company's stock closed at GBX 1,404.50 ($18.87) with a 12-month range between GBX 1,242.50 ($16.69) and GBX 1,678.68 ($22.55).
• Analysts have mixed views on GSK, with price targets ranging from GBX 1,400 ($18.80) to GBX 2,000 ($26.86), indicating varying confidence in the company's future performance.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 9 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were acquired at an average cost of GBX 1,408 ($18.91) per share, for a total transaction of £126.72 ($170.21).

GSK Stock Performance

GSK stock traded up GBX 0.50 ($0.01) on Tuesday, reaching GBX 1,404.50 ($18.87). 7,157,327 shares of the company were exchanged, compared to its average volume of 13,106,199. GSK plc has a 12 month low of GBX 1,242.50 ($16.69) and a 12 month high of GBX 1,678.68 ($22.55). The stock's fifty day moving average price is GBX 1,425.58 and its 200 day moving average price is GBX 1,428.05. The firm has a market capitalization of £56.99 billion, a PE ratio of 22.69, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported GBX 75.30 ($1.01) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent analyst reports. Shore Capital reissued a "buy" rating and issued a GBX 2,000 ($26.86) price target on shares of GSK in a research report on Wednesday, July 30th. JPMorgan Chase & Co. dropped their price target on shares of GSK from GBX 1,460 ($19.61) to GBX 1,400 ($18.80) and set an "underweight" rating on the stock in a research report on Monday, August 4th. Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 ($21.49) price target on shares of GSK in a research report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a GBX 1,450 ($19.48) price target on shares of GSK in a research report on Thursday, July 31st.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.